Skip to content

Intravenous Lidocaine Infusion Reduce Postoperative Pulmonary Complications in Patients Undergoing Minimally Invasive Esophagectomy

Effect of Intravenous Lidocaine Infusion on Postoperative Pulmonary Complications in Patients Undergoing Minimally Invasive Esophagectomy: a Double-center, Double-blind, Randomized Controlled Trial

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06138041
Enrollment
770
Registered
2023-11-18
Start date
2025-02-01
Completion date
2025-08-30
Last updated
2024-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pneumonia, Postoperative Pulmonary Atelectasis, Postoperative Pulmonary Edema

Brief summary

The goal of this double-center, double-blind, randomized controlled clinical trial is to compare the effect of intravenous lidocaine infusion on postoperative pulmonary complications in patients undergoing minimally invasive esophagectomy. The main question it aims to answer are whether intravenous lidocaine reduce postoperative pulmonary complications in patients undergoing minimally invasive esophagectomy. Participants will be given intravenous lidocaine infusion in lidocaine group or placebo in control group.

Interventions

Lidocaine bolus of 2mg/kg after induction , and then continuous infusion with 2 mg/kg/h until the participate transfer out of postoperative anesthesia care unit.

DRUGSaline

Same volume of normal saline in bolus and continuous infusion as lidocaine group.

Sponsors

Sichuan Cancer Hospital and Research Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

Patients between 18 and 85 years of age with a recent schedule for MIE are screened for this study. Patients who show clear consciousness and ASA status I - III will be included as eligible participants.

Exclusion criteria

The

Design outcomes

Primary

MeasureTime frameDescription
Incidence of PPCs1, 2, 3, 4, 5, 6, 7 days after surgeryPulmonary complications is defined as one or more of the following complications: respiratory infection; respiratory failure; pneumothorax;atelectasis; pleural effusion; bronchospasm; aspiration pneumonitis; anastomotic fistula

Secondary

MeasureTime frame
respiratory infection1, 2, 3, 4, 5, 6, 7 days after surgery
respiratory failure1, 2, 3, 4, 5, 6, 7 days after surgery
pneumothorax;atelectasis1, 2, 3, 4, 5, 6, 7 days after surgery
pleural effusion1, 2, 3, 4, 5, 6, 7 days after surgery
additional rescue analgesics use24 and 48 hours after surgery
aspiration pneumonitis1, 2, 3, 4, 5, 6, 7 days after surgery
anastomotic fistula1, 2, 3, 4, 5, 6, 7 days after surgery
moderate to severe pain within 24 and 48 hours at rest and when coughing24 and 48 hours after surgery
moderate to severe pain within 24 and 48 hours at coughing24 and 48 hours after surgery
bronchospasm1, 2, 3, 4, 5, 6, 7 days after surgery

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026